A multinational manufacturer of cardiovascular devices recently engaged SeerPharma to conduct a comprehensive mock US FDA audit of their operations in Singapore. The audit was conducted against US FDA 21 CFR Part 820 – Quality System Regulation (21 CFR 820). SeerPharma reviewed relevant documentation remotely and then spent three days on-site reviewing manufacturing operations and activities.
SeerPharma assessed the following areas of the company’s operations over three days.
Process | 21 CFR 820 Reference |
Quality System
|
Sec. 820.5 Quality System |
Management Responsibility
|
Sec. 820.20 Management Responsibility |
Document Controls
|
Sec. 820.40 Document Controls |
Corrective and Preventive Action
|
Sec 820.90 Nonconforming Product |
Design Controls
|
Sec. 820.30 Design Controls |
Purchasing Controls
|
Sec 820.50 Purchasing Controls |
Production and Process Controls
|
Sec 820.70 Production and Process Controls Sec 820.50 Purchasing Controls |
Measurement and Analysis
|
Sec 820.22 Quality Audit |
Records
|
Sec 820.180 General Requirements Sec 820.184 Device History Record |
Following the mock FDA audit, SeerPharma presented a comprehensive report to the client classifying findings as follows:
The mock inspection and observations by SeerPharma are intended to assist the client in preparing for an impending US FDA inspection.
SeerPharma has over 35 years of industry experience conducting mock GMP regulatory inspections by health authorities such as the US FDA, MHRA, TGA, HSA and other PIC/S member authorities. Our team of seasoned experts can provide a comprehensive independent review of your operations, to help you prepare for regulatory GMP inspections.
Visit https://www.seerpharma.com/services/qa-and-gmp-consulting/auditing to learn more about SeerPharma’s auditing services and contact us if you’d like support with mock GMP regulatory inspections.